NCT02175433 2024-11-01
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Astellas Pharma Inc
Phase 1 Completed
Astellas Pharma Inc
Astellas Pharma Inc